Phosphagenics Reports Superior Pre Clinical Cholesterol Results From APA 01 And Atorvastatin Combination

Phosphagenics Limited (”Phosphagenics”) (ASX: POH, AIM: PSG, OTCQX: PPGNY) announced results of a pre-clinical study demonstrating that the combination of its APA- 01 product candidate and the statin atorvastatin (Lipitor(TM)) significantly reduced serum lipids and inflammatory proteins involved in the development of atherosclerosis.

More: continued here

Filed under: Statins on February 7th, 2008